Literature DB >> 28759366

Calling time on the immunotherapy gold rush.

.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28759366     DOI： 10.1016/S1470-2045(17)30521-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  9 in total

1.  MALDI-MSI of Immunotherapy: Mapping the EGFR-Targeting Antibody Cetuximab in 3D Colon-Cancer Cell Cultures.

Authors:  Xin Liu; Jessica K Lukowski; Colin Flinders; Seungil Kim; Rebecca A Georgiadis; Shannon M Mumenthaler; Amanda B Hummon
Journal:  Anal Chem       Date:  2018-12-07       Impact factor: 6.986

2.  Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting.

Authors:  V C Sandulache; Y L Lei; L E Heasley; M Chang; C I Amos; E M Sturgis; E Graboyes; E Y Chiao; N Rogus-Pulia; J Lewis; A Madabhushi; M J Frederick; A Sabichi; M Ittmann; W G Yarbrough; C H Chung; R Ferrarotto; Weiyuan Mai; H D Skinner; U Duvvuri; P Gerngross; A G Sikora
Journal:  Oral Oncol       Date:  2019-10-22       Impact factor: 5.337

3.  CD68 and CD83 immune populations in non-metastatic axillary lymph nodes are of prognostic value for the survival and relapse of breast cancer patients.

Authors:  Carlos López; Ramón Bosch; Anna Korzynska; Marcial García-Rojo; Gloria Bueno; Joan Francesc García-Fontgivell; Salomé Martínez González; Andrea Gras Navarro; Esther Sauras Colón; Júlia Casanova Ribes; Lukasz Roszkowiak; Daniel Mata; Meritxell Arenas; Junior Gómez; Albert Roso; Marta Berenguer; Silvia Reverté-Villarroya; Montserrat Llobera; Jordi Baucells; Marylène Lejeune
Journal:  Breast Cancer       Date:  2022-02-08       Impact factor: 4.239

Review 4.  Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy.

Authors:  Rachael M Zemek; Wee Loong Chin; Anna K Nowak; Michael J Millward; Richard A Lake; W Joost Lesterhuis
Journal:  Front Immunol       Date:  2020-02-18       Impact factor: 7.561

5.  Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy.

Authors:  Caitlin M Tilsed; Thomas H Casey; Emma de Jong; Anthony Bosco; Rachael M Zemek; Joanne Salmons; Graeme Wan; Michael J Millward; Anna K Nowak; Richard A Lake; Willem Joost Lesterhuis
Journal:  Front Oncol       Date:  2022-03-24       Impact factor: 6.244

Review 6.  Emerging role of RNA sensors in tumor microenvironment and immunotherapy.

Authors:  Rui Yang; Sihui Yu; Tianhan Xu; Jiawen Zhang; Sufang Wu
Journal:  J Hematol Oncol       Date:  2022-04-12       Impact factor: 17.388

7.  Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice.

Authors:  Rachael M Zemek; Wee Loong Chin; Vanessa S Fear; Ben Wylie; Thomas H Casey; Cath Forbes; Caitlin M Tilsed; Louis Boon; Belinda B Guo; Anthony Bosco; Alistair R R Forrest; Michael J Millward; Anna K Nowak; Richard A Lake; Timo Lassmann; W Joost Lesterhuis
Journal:  Nat Commun       Date:  2022-08-19       Impact factor: 17.694

8.  Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review.

Authors:  Houssein Safa; Monica Tamil; Philippe E Spiess; Brandon Manley; Julio Pow-Sang; Scott M Gilbert; Firas Safa; Brian D Gonzalez; Laura B Oswald; Adele Semaan; Adi Diab; Jad Chahoud
Journal:  J Natl Cancer Inst       Date:  2021-05-04       Impact factor: 13.506

9.  Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.

Authors:  Alyson Haslam; Vinay Prasad
Journal:  JAMA Netw Open       Date:  2019-05-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.